不同年龄组神经胶质瘤中 IDH 突变的频率和意义尚不完全清楚。我们对 IDH 突变神经胶质瘤患者进行了多中心回顾性年龄分层比较，以确定临床基因组特征、治疗和结果的年龄特异性差异。来自 IDH 突变、分级患者的临床、组织学和测序数据2-4 个神经胶质瘤，是从 2013 年至 2019 年期间从合作机构收集的。患者被分为儿童（<19岁）、青少年（19-39岁）或老年人（≥40岁）。使用费舍尔精确检验或方差分析对不同年龄组的临床表现、治疗、组织学和分子特征进行比较。 Cox 比例风险回归用于确定年龄和其他协变量与总生存期 (OS) 和无进展生存期 (PFS) 的关联。我们通过临床数据确定了 379 名 IDH 突变神经胶质瘤患者（204 年）的队列。共有 155 例（41%）少突胶质细胞瘤和 224 例（59%）星形细胞瘤。与儿童和成人组相比，YA 的 PFS 和中位恶变时间 (MT) 显着缩短，但 OS 没有显着差异。在多变量分析中调整病理类型、切除范围和前期治疗后，YA 组可独立预测 PFS 短于儿童和成人组。在星形细胞瘤中，CDK4/6 拷贝数扩增与较短的 PFS 和较短的 OS 相关。在少突胶质细胞瘤中，PIK3CA 和 CDKN2A/2B 的改变与较短的 OS 相关。IDH 突变胶质瘤 YA 患者的 PFS 和 MT 时间显着较短，但与儿童和成人组相比，OS 没有差异。治疗方法因患者年龄而异，需要进一步研究作为可寻址的年龄相关结果驱动因素。© 作者 2024。由牛津大学出版社代表神经肿瘤学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

The frequency and significance of IDH mutations in glioma across age groups is incompletely understood. We performed a multi-center retrospective age-stratified comparison of patients with IDH-mutant gliomas to identify age-specific differences in clinico-genomic features, treatments, and outcomes.Clinical, histologic, and sequencing data from patients with IDH-mutant, grade 2-4 gliomas, were collected from collaborating institutions between 2013-2019. Patients were categorized as pediatric (<19y), YA (19-39y) or older adult (≥40y). Clinical presentation, treatment, histologic, and molecular features were compared across age categories using Fisher's exact test or analysis-of-variance. Cox proportional-hazards regression was used to determine association of age and other covariates with overall (OS) and progression-free survival (PFS).We identified a cohort of 379 patients (204 YA) with IDH-mutant glioma with clinical data. There were 155 (41%) oligodendrogliomas and 224 (59%) astrocytomas. YA showed significantly shorter PFS and shorter median time-to-malignant transformation (MT) compared to pediatric and adult groups, but no significant OS difference. Adjusting for pathology type, extent of resection, and upfront therapy in multivariable analysis, the YA group was independently prognostic of shorter PFS than pediatric and adult groups. Among astrocytomas, CDK4/6 copy number amplifications were associated with both shorter PFS and shorter OS. Among oligodendrogliomas, PIK3CA and CDKN2A/2B alterations were associated with shorter OS.IDH-mutant glioma YA patients had significantly shorter PFS and time to MT but did not differ in OS compared to pediatric and adult groups. Treatment approach varied significantly by patient age and warrant further study as addressable age-associated outcome drivers.© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.